PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2024-02-09 (4)

Date Title Company
09-Feb-2024 Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 Businesswire